Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiProtekt network

被引:26
作者
Henes, M. [1 ]
Henes, J. C. [2 ]
Neunhoeffer, E. [1 ]
Von Wolff, M.
Schmalzing, M. [2 ]
Koetter, I. [2 ]
Lawrenz, B. [1 ]
机构
[1] Univ Tuebingen Hosp, Univ Hosp Women, Tubingen, Germany
[2] Univ Tuebingen Hosp, Ctr Interdisciplinary Clin Immunol Rheumatol & Au, Tubingen, Germany
关键词
Autoimmune disease; systemic lupus erythematosus; fertility preservation; cyclophosphamide; FertiPROTEKT; CRYOPRESERVED OVARIAN TISSUE; INTRAVENOUS CYCLOPHOSPHAMIDE; PULSE CYCLOPHOSPHAMIDE; SUSTAINED AMENORRHEA; PREMENOPAUSAL WOMEN; FAILURE; HORMONE; AUTOTRANSPLANTATION; TRANSPLANTATION; CHEMOTHERAPY;
D O I
10.1177/0961203312442753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Despite new treatment options, some patients with systemic lupus erythematosus (SLE) need to be treated with the cytotoxic agent cyclophosphamide (CYC). Unlike malignant disease, there are no recommendations for ovarian protection in SLE. The clinical experience of the FertiPROTEKT network as well as recommendations after literature review will be presented in this paper. Methods: Retrospective analyses of counselling and treatment data from the FertiPROTEKT register with special respect to SLE patients under 40 years prior to planned CYC treatment. Results: A total of 2836 patients were advised prior to cytotoxic treatment in one of the FertiPROTEKT centres during January 2007 to November 2011. Of those, 68 patients (mean age 25 +/- 6.07years) were counselled for severe SLE. Only five women did not make use of a fertility preservation method. Sixty-three patients (92.6%) decided in favour of a fertility preservation method. The largest proportion (91.2%) opted for treatment with a GnRH analogue. Ovarian tissue removal for cryoconservation was performed in 16 patients (25%). Stimulation therapy for cryoconservation of fertilized egg cells was performed in three patients (4.4%). Conclusions: When counselling patients with SLE for fertility preservation one has to be aware of the disease-specific risks. According to the literature, a safe and effective option in SLE up to now has been the use of a GnRH analogue. Cryoconservation of ovarian tissue must still be seen as an experimental treatment, but as data on removal, cryoconservation, retransplantation and pregnancies are steadily rising, this presents a promising option for young SLE patients. Cryoconservation of oocytes must be very critically evaluated due to the need for a stimulation therapy and should only be performed after particular consideration of the individual risks. Lupus (2012) 21, 953-958.
引用
收藏
页码:953 / 958
页数:6
相关论文
共 28 条
[1]   LONG-TERM GONADOTROPIN-RELEASING-HORMONE AGONIST THERAPY - THE EVOLVING ISSUE OF STEROIDAL ADD-BACK PARADIGMS [J].
ADASHI, EY .
HUMAN REPRODUCTION, 1994, 9 (07) :1380-1397
[2]   Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue [J].
Andersen, Claus Yding ;
Rosendahl, Mikkel ;
Byskov, Anne Grete ;
Loft, Anne ;
Ottosen, Christian ;
Dueholm, Margit ;
Schmidt, Kirsten L. T. ;
Andersen, Anders Nyboe ;
Ernst, Erik .
HUMAN REPRODUCTION, 2008, 23 (10) :2266-2272
[3]   Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome [J].
Bellver, Jose ;
Pellicer, Antonio .
FERTILITY AND STERILITY, 2009, 92 (06) :1803-1810
[4]   Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis [J].
Ben-Aharon, Irit ;
Gafter-Gvili, Anat ;
Leibovici, Leonard ;
Stemmer, Salomon M. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) :803-811
[5]   Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy [J].
Blumenfeld, Z ;
Shapiro, D ;
Shteinberg, M ;
Avivi, I ;
Nahir, M .
LUPUS, 2000, 9 (06) :401-405
[6]   RISK FOR SUSTAINED AMENORRHEA IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS RECEIVING INTERMITTENT PULSE CYCLOPHOSPHAMIDE THERAPY [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHAN, EM ;
YARBORO, CH ;
KLIPPEL, JH ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (05) :366-369
[7]  
Casoli P, 1997, J RHEUMATOL, V24, P1639
[8]   Hormonal Strategies for Fertility Preservation in Patients Receiving Cyclophosphamide to Treat Glomerulonephritis: A Nonrandomized Trial and Review of the Literature [J].
Cigni, Alessandro ;
Faedda, Rossana ;
Atzeni, Maria Maddalena ;
Pileri, Piera Veronica ;
Alagna, Sergio ;
Rovasio, Pierpaolo ;
Satta, Andrea Ercole ;
Loi, Maria Rita ;
Sini, Annalisa ;
Satta, Vincenzo ;
Masala, Antonio .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (05) :887-896
[9]   Ovarian Preservation by GnRH Agonists during Chemotherapy: A Meta-Analysis [J].
Clowse, Megan E. B. ;
Behera, Millie A. ;
Anders, Carey K. ;
Copland, Susannah ;
Coffman, Cynthia J. ;
Leppert, Phyllis C. ;
Bastian, Lori A. .
JOURNAL OF WOMENS HEALTH, 2009, 18 (03) :311-319
[10]   Fertility preservation: Successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease [J].
Demeestere, Isabelle ;
Simon, Philippe ;
Emiliani, Serena ;
Delbaere, Anne ;
Englert, Yvon .
ONCOLOGIST, 2007, 12 (12) :1437-1442